Intravenous (IV) stem cell therapy is one of the most actively researched frontiers in regenerative medicine. By delivering stem cells directly into the bloodstream, this approach allows the cells to circulate throughout the body, potentially migrating to areas of inflammation, tissue damage, or immune dysregulation.
The field is growing rapidly, with hundreds of clinical trials taking place across the globe. Patient interest in stem cell IV options is also growing, with thousands across the country prioritizing health optimization and enduring pain relief. This guide explores stem cell IV therapy, how it works, and the latest studies.
How IV Stem Cell Therapy Works
Most IV protocols use mesenchymal stem cells (MSCs) sourced from umbilical cord tissue, bone marrow, or adipose (fat) tissue. MSCs are recognized for their ability to release anti-inflammatory signals and interact with the immune system.
When MSCs are administered intravenously, they enter the circulatory system and home toward areas of active inflammation or injury.
Rather than directly replacing damaged cells, MSCs work primarily through paracrine signaling, releasing cytokines, growth factors, and extracellular vesicles that influence surrounding tissue and immune cells. This mechanism makes systemic IV delivery particularly relevant for conditions driven by chronic inflammation or immune dysregulation, where whole-body exposure to these signals may be therapeutically meaningful.
Conditions in Focus with Stem Cell IV Therapy Studies
While stem cells are currently only approved for addressing pain and wound healing, there is ongoing research and development on stem cell IV therapy and its potential.
Autoimmune Conditions
Multiple sclerosis, lupus, rheumatoid arthritis, and Crohn’s disease are among the most studied targets. MSCs are believed to modulate overactive immune responses — reducing the attack on the body’s own tissues without broadly suppressing immune function. MS in particular has been the subject of multiple phase I and II trials examining both IV and other delivery routes.
Neurological Conditions
ALS, Parkinson’s disease, stroke recovery, and autism spectrum disorder (ASD) are being studied in formal clinical settings. IV-delivered stem cells are under study as a means to reduce neuroinflammation, support neuron survival, and potentially slow disease progression. Duke University’s Marcus Center for Cellular Cures has conducted several notable trials in this space.
Cardiovascular Disease
Heart failure has been evaluated in randomized controlled trials using IV-infused umbilical cord MSCs. The RIMECARD trial was a landmark study in this area, with results showing patient improvements in cardiac function and quality of life.
Pulmonary Conditions
Because IV-administered cells pass through the lungs first, some researchers believe this first-pass concentration may be therapeutically useful for pulmonary conditions, such as COPD, specifically.
Orthopedic and Musculoskeletal Conditions
While local injection remains the primary delivery method for joint conditions, systemic IV therapy is being studied as a complementary treatment for conditions such as osteoarthritis and inflammatory musculoskeletal disease, where systemic inflammation plays a role.
Kidney Disease
Several institutions, including Mayo Clinic, are evaluating IV bone marrow-derived MSCs for chronic kidney disease. These protocols assess both safety and early signals of renal function improvement.
Diabetes
Stem cell IV therapy is also under review as an option for Type 1 and Type 2 diabetes. For Type 1, the focus is on modulating the immune destruction of insulin-producing beta cells. A pivotal Phase I/II/III trial by Vertex Pharmaceuticals (VX-880) has shown that all 12 patients who received the target dose demonstrated evidence of islet cell engraftment, with 11 of 12 reducing or eliminating their dependence on exogenous insulin.
Aging Frailty
Multiple trials have examined IV MSC infusions as a potential intervention for age-related physical frailty, measuring outcomes such as mobility, energy, and immune function in older adults.
| Condition | Proposed Mechanism | Current Evidence Stage |
| Multiple Sclerosis | Immune modulation, neuroprotection | Phase I/II clinical trials |
| Rheumatoid Arthritis | Anti-inflammatory cytokine release | Phase I/II trials |
| ALS | Neuroprotective, reduces neuroinflammation | Phase I/II trials |
| Heart Failure | Cardiac remodeling support, anti-fibrotic effects | Phase I/II RCTs completed |
| COPD / Pulmonary Fibrosis | Pulmonary anti-inflammation via the first-pass effect | Phase I/II trials |
| Osteoarthritis | Cartilage support, systemic anti-inflammation | Small studies + IV adjunct protocols |
| Type 1 Diabetes | Immune modulation, beta cell preservation | Phase I/II/III pivotal trial (VX-880) |
| Chronic Kidney Disease | Renal tissue repair, anti-fibrotic signaling | Phase I trials (Mayo Clinic, others) |
| Stroke Recovery | Neuroprotection reduces infarct inflammation | Phase I/II trials |
| Autism Spectrum Disorder | Neuroinflammation reduction | Phase I completed, Phase II underway |
| Aging Frailty | Immune rejuvenation, anti-senescent signaling | Phase I/II RCTs |
| Lupus / Crohn’s Disease | Systemic immune regulation | Phase I/II trials |
The Science Behind IV Delivery of Stem Cells
Understanding how IV stem cell therapy works can help provide insight into its potential value for a broad range of patient profiles.
- Moderate inflammation
Data from stem cell studies show IV stem cells moderate inflammation by releasing molecules that signal immune cells to shift from an aggressive, pro-inflammatory state to a regulatory, tissue-protective condition.
- Limited immune response
MSCs are also considered “immune-privileged”. They are allogeneic (donor-derived) cells that are generally tolerated by the recipient’s immune system without requiring the aggressive immunosuppression typical of organ transplants. This makes it feasible to use off-the-shelf, manufactured cell products at scale — a significant practical advantage over alternatives requiring cells from the patient’s own body.
- Systemic impact
The systemic nature of IV delivery means that a single infusion may influence multiple organ systems simultaneously. For patients with conditions that affect the whole body, this broad reach may be more therapeutically relevant than a localized treatment approach.
| Potential Stem Cell IV Benefit | Explanation | Supporting Evidence |
| Reduced Systemic Inflammation | MSCs release anti-inflammatory cytokines throughout the body | Most consistently observed finding across trials |
| Immune System Modulation | May calm overactive immune responses without full immunosuppression | Supported across autoimmune trial data |
| Tissue Repair Signaling | Stem cells signal resident cells to begin regenerative processes | Documented in studies |
| Non-Surgical Delivery | IV infusion avoids the need for surgical or invasive access | Established delivery advantage |
| Systemic Reach | Circulates body-wide; relevant for multi-system or diffuse conditions | Theoretically and practically supported |
| Scalability | Allogeneic products can be manufactured at scale for broader access | Supported by current GMP manufacturing protocols |
Stem Cell IV Therapy Vs. Surgery and Local Injections
| Factor | IV Stem Cell Therapy | Pharmaceutical / Biologic Drugs | Local Stem Cell Injection | Surgery |
| Invasiveness | Low | Low to moderate | Moderate (targeted injection) | High |
| Evidence Base | Emerging; active phase I/II/III trials | Strong for most conditions | Moderate for joint conditions | Strong for structural issues |
| Target Specificity | Systemic (body-wide) | Varies by drug | High (local tissue) | High |
| Duration of Effect | Variable; under ongoing study | Ongoing maintenance typically required | Months to years (reported) | Typically long-term |
| Availability | Specialized clinics and trial centers | Widely available | Specialized clinics | Widely available |
| Best Suited For | Systemic, inflammatory, or multi-tissue conditions | Most chronic conditions | Localized joint or tissue disease | Structural or mechanical damage |
Notable IV Stem Cell Clinical Trials
Stem Cell IV therapy is currently only available for targeted pain relief and wound healing applications.
However, medical trials are ongoing with new research data released regularly. The following trials represent some of the most significant formal research into IV stem cell therapy.
RIMECARD Trial — Heart Failure (NCT01739777)
What it tested: IV infusion of umbilical cord-derived MSCs in patients with chronic heart failure and reduced ejection fraction.
Result: This was the first double-blind, randomized, placebo-controlled trial to confirm the safety and feasibility of IV UC-MSC infusion for heart failure. Patients in the treatment group showed improvements in left ventricular function and quality of life compared to placebo.
Vertex VX-880 — Type 1 Diabetes (NCT04786262)
What it tested: IV infusion of stem cell-derived islet cells in patients with Type 1 diabetes.
Result: All 12 patients receiving the target dose showed evidence of islet cell engraftment, and 11 of 12 reduced or eliminated their need for exogenous insulin. The trial has since been converted into a pivotal Phase I/II/III study, moving the therapy closer to potential market approval.
MSC Trial for Crohn’s Disease (NCT01155362)
What it tested: IV infusion of MSCs at varying doses in patients with active Crohn’s disease, measuring disease activity index outcomes.
Result: Meaningful reductions in Crohn’s disease activity scores were reported at 150 million cells per patient per dose, contributing to the broader understanding of optimal IV dosing for MSC therapies.
Mayo Clinic MSC for Chronic Kidney Disease
What it tested:
A single IV infusion of allogeneic bone marrow-derived MSCs in patients with chronic kidney disease, focusing on safety and early efficacy signals.
Result: One of the first structured US investigations into IV stem cells for CKD, with follow-up safety evaluations ongoing. Results are contributing to the foundational safety data needed to advance this indication.
Book Stem Cell IV Therapy in Miami
STEMS Health is Miami’s leader for stem cell IV therapy. The clinic welcomes patients from across the United States to benefit from the latest regenerative care services within a luxury healthcare space. Their board-certified doctors have decades of experience building custom treatment plans for patients of various health backgrounds.
Schedule your free stem cell IV therapy consultation today to explore the latest treatment options available through STEMS Health.
Frequently Asked Questions
What is the FDA’s current position on IV stem cell therapy?
The FDA has approved a small number of stem cell therapies for specific pain-related applications. The most recent was Ryoncil in December 2024 — the first MSC-based therapy approved for pediatric steroid-refractory acute graft versus host disease. For most other conditions, IV stem cell treatments are being evaluated within formal clinical trial frameworks. Patients seeking treatment outside of a registered trial should verify that any provider is operating under appropriate regulatory oversight.
What type of stem cells are typically used in IV infusions?
Most IV protocols use mesenchymal stem cells (MSCs), with umbilical cord tissue being among the most common sources due to its accessibility and favorable immunological properties. Bone marrow-derived and adipose-derived MSCs are also used. Allogeneic (donor) cells are increasingly preferred for scalability, while autologous (patient’s own) cells remain relevant in certain protocols.
How long does an IV stem cell infusion take, and what does the process involve?
Most IV stem cell infusions are administered over 30 to 90 minutes in an outpatient clinical setting. Patients typically receive premedication before the infusion, followed by a monitoring period of one to two hours. The process does not require hospitalization and is generally well-tolerated across the clinical trials conducted to date.
How many IV stem cell treatments are typically needed?
This varies significantly by condition, protocol, and provider. Some trials use a single infusion; others involve two to six infusions spaced weeks or months apart. Establishing optimal dosing schedules for specific conditions remains one of the more active areas of investigation in the field.
